A Fructus Forsythiae and Radix Astragali compound preparation, and a preparation method therefor and a use thereof is provided. Traditional Chinese medicine formulation components consist of the following raw materials or raw material extracts in parts by mass: 9-11 parts of Flos Lonicerae, 9-11 parts of Fructus Forsythiae, 9-11 parts of Radix Scutellariae, 9-11 parts of Herba Artemisiae Annuae, 9-11 parts of Radix Astragali, 9-11 parts of stir-fried Rhizoma Atractylodis Macrocephalae, 9-11 parts of Herba Pogostemonis, 5-7 parts of Radix Saposhnikoviae, 9-11 parts of Radix Ophiopogonis, and 5-7 parts of Radix Glycyrrhizae. The components can be made into an oral liquid, a granule, a dissolved medicine, or a tablet. Further disclosed is a use of the Fructus Forsythiae and Radix Astragali compound preparation in preparation of medicines for preventing and/or treating a viral influenza disease.

A Fructus Forsythiae and Radix Astragali compound preparation, and a preparation method therefor and a use thereof is provided. Traditional Chinese medicine formulation components consist of the following raw materials or raw material extracts in parts by mass: 9-11 parts of Flos Lonicerae, 9-11 parts of Fructus Forsythiae, 9-11 parts of Radix Scutellariae, 9-11 parts of Herba Artemisiae Annuae, 9-11 parts of Radix Astragali, 9-11 parts of stir-fried Rhizoma Atractylodis Macrocephalae, 9-11 parts of Herba Pogostemonis, 5-7 parts of Radix Saposhnikoviae, 9-11 parts of Radix Ophiopogonis, and 5-7 parts of Radix Glycyrrhizae. The components can be made into an oral liquid, a granule, a dissolved medicine, or a tablet. Further disclosed is a use of the Fructus Forsythiae and Radix Astragali compound preparation in preparation of medicines for preventing and/or treating a viral influenza disease.

A Fructus Forsythiae and Radix Astragali compound preparation, and a preparation method therefor and a use thereof is provided. Traditional Chinese medicine formulation components consist of the following raw materials or raw material extracts in parts by mass: 9-11 parts of Flos Lonicerae, 9-11 parts of Fructus Forsythiae, 9-11 parts of Radix Scutellariae, 9-11 parts of Herba Artemisiae Annuae, 9-11 parts of Radix Astragali, 9-11 parts of stir-fried Rhizoma Atractylodis Macrocephalae, 9-11 parts of Herba Pogostemonis, 5-7 parts of Radix Saposhnikoviae, 9-11 parts of Radix Ophiopogonis, and 5-7 parts of Radix Glycyrrhizae. The components can be made into an oral liquid, a granule, a dissolved medicine, or a tablet. Further disclosed is a use of the Fructus Forsythiae and Radix Astragali compound preparation in preparation of medicines for preventing and/or treating a viral influenza disease.

[Problem] To provide a novel medicine that is capable of promoting cholesterol metabolism to thereby treat, ameliorate or prevent various symptoms associated with increase in blood cholesterol level. [Solution] The present inventors newly found that arctigenin has an effect of promoting the conversion of cholesterol into bile acid. The present invention provides a bile acid synthesis promoter, a composition for promoting bile acid synthesis and a food composition for promoting bile acid synthesis each comprising arctigenin and/or arctiin as active ingredient(s).

The present invention provides a method of treating and/or preventing pulmonary hypertension in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a bioactive peptide preparation derived from at least one botanical source.

The present invention provides a method of treating and/or preventing pulmonary hypertension in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a bioactive peptide preparation derived from at least one botanical source.

The present invention provides a method of treating and/or preventing pulmonary hypertension in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a bioactive peptide preparation derived from at least one botanical source.

The solution provides a method for separating a Chinese traditional medicine composition. To explain a pharmacological effect mechanism of a medicine made of two or more components and scientific content in rules of compatibility among components of a compound medicine, systematic researches on the material basis is very necessary. Accordingly, deep researches are done on chemical components of the pharmaceutical composition in the solution, and eight compounds are separated, which are 10-O-(p-hydroxycinnamoyl)-adoxosidic acid, aloe-emodin-8-O-β-D-glucopyranoside, quercitrin, matairesinol-4′-O-glucoside, liquiritin apioside, epi-vogeloside, vogeloside and ethyl caffeate, which provides a new quality control method for the composition in the solution.

The solution provides a method for separating a Chinese traditional medicine composition. To explain a pharmacological effect mechanism of a medicine made of two or more components and scientific content in rules of compatibility among components of a compound medicine, systematic researches on the material basis is very necessary. Accordingly, deep researches are done on chemical components of the pharmaceutical composition in the solution, and eight compounds are separated, which are 10-O-(p-hydroxycinnamoyl)-adoxosidic acid, aloe-emodin-8-O-β-D-glucopyranoside, quercitrin, matairesinol-4′-O-glucoside, liquiritin apioside, epi-vogeloside, vogeloside and ethyl caffeate, which provides a new quality control method for the composition in the solution.

The present invention provides a method of treating or delaying the onset of Alzheimer's disease or other neurological diseases in a patient having or at risk of developing Alzheimer's disease or other neurological diseases comprising administering to the subject an effective amount of an anti-angiogenic agent. In particular, the present invention provides a method of treating and/or delaying the onset of Alzheimer's disease or other neurological diseases by inhibiting Angiopoietin-2 mediated Tie-2 angiogenic pathway comprising administering to the subject an effective amount of an inhibitor of the Angiopoietin-2 mediated Tie-2 angiogenic pathway.